This phase I study was designed to determine the optimal dosages of a novel repetitive high-dose therapy regimen for patients with metastatic breast cancer (MBC). The planned treatment was three cycles of high-dose cyclophosphamide, thiotepa and docetaxel delivered every 35 days with progressive dose-escalation in successive cohorts. Each cycle was supported by peripheral blood progenitor cells (PBPC) and filgrastim. Eighteen patients were entered into this trial. Of the planned 54 treatment cycles, 44 were delivered and 11 patients completed all three cycles. The dose-limiting toxicities were interstitial pneumonitis and mucositis with moderately severe diarrhea (n = 3) and rash (n = 3). There were no treatment-related deaths. Of the 17 patients with evaluable disease, 16 patients responded with six patients achieving a complete remission and an additional four patients achieving no detectable disease (negative restaging including PET scan) but a persistently abnormal bone scan. At a median follow-up of 12 months, median progression-free survival was 11 months with the median overall survival not reached. must still be considered investigational. 6-8 Nonetheless, one approach considered worthy of further investigation is the use of repeated cycles of HDT. 6 We have been interested in developing protocols utilizing repetitive cycles of HDT for patients with MBC, based on administering three cycles of HDT, with each cycle supported by PBPCs.
must still be considered investigational. [6] [7] [8] Nonetheless, one approach considered worthy of further investigation is the use of repeated cycles of HDT. 6 We have been interested in developing protocols utilizing repetitive cycles of HDT for patients with MBC, based on administering three cycles of HDT, with each cycle supported by PBPCs. [9] [10] [11] The primary objective of this study was to develop a suitable regimen that could be delivered largely on an out-patient basis (ie not requiring parenteral nutrition or opiate analgesia for gastrointestinal toxicity) that could subsequently be tested in a randomized trial in patients with MBC.
We have previously reported our results of repetitive cycles of HDT using a combination of ifosfamide, thiotepa and paclitaxel (ITP). 9 However, in that study, two patients developed grade 3 renal tubular acidosis (RTA) and we later recognized a further case of RTA in the subsequent phase II study of this regimen. 12 Consequently, it was considered that this ifosfamide-related side-effect was unacceptable and in the current study we substituted cyclophosphamide for ifosfamide. Furthermore, as the planned randomized study was to utilize docetaxel in the conventionaldose therapy (CDT) arm, we have substituted docetaxel for paclitaxel in this high-dose therapy regimen.
Materials and methods

Eligibility criteria
Patients with histologically proven metastatic or locally advanced breast cancer were eligible for entry into this prospective trial. Sufficient PBPCs to support these three cycles of HDT were collected prior to the initiation of HDT (see below). Patients were ineligible if they had a history of prior docetaxel therapy, ventricular arrhythmia, myocardial infarction within 6 months of enrolment, congestive heart failure, hypersensitivity to any of the study drugs, were pregnant or lactating, had an ECOG performance status Ͼ2, life expectancy of less than 2 months, absolute neutrophil count (ANC) Ͻ1.5 ϫ 10 9 /l, platelet count Ͻ100 ϫ 10 9 /l, serum bilirubin above the upper limit of normal range (ULN), aspartate/alanine transaminase Ͼ2.5 × ULN, alka-line phosphatase Ͼ5 × ULN (except those with bone metastases in the absence of liver disorder) or creatinine Ͼ1.5 × ULN. Written informed consent was obtained from all patients and the protocol was approved by the Institutional Ethics Committee (IEC) of the Peter MacCallum Cancer Institute with all serious adverse events immediately reported to the IEC and reviewed.
Mobilization and collection of PBPCs
One objective of management was to obtain PBPCs as soon as possible after trial entry so patients could proceed rapidly to the HDT phase. We and others have previously demonstrated the effectiveness of docetaxel with granulocyte colony-stimulating factor (G-CSF) to mobilize PBPCs in patients with breast cancer. 13, 14 Consequently, patients received a single cycle of docetaxel (Taxotere, Rhône-Poulenc Rorer Australia, Pty Ltd, Baulkham Hills, NSW, Australia) (100 mg/m 2 ). Dexamethasone (8 mg) was administered over 3 days for a total of six doses commencing the night before chemotherapy and completed the evening of the day after. Twenty-four hours after completing docetaxel, patients received daily subcutaneous injections of G-CSF (Neupogen, Amgen Australasia Pty Ltd, Sydney, Australia) at a dose of 10 g/kg, which continued until the last day of apheresis.
The apheresis procedure and assessment of autograft hematological parameters has been described previously. 13, 15 Apheresis was repeated until sufficient cells to support three separate cycles of HDT had been collected, ie a minimum target of 4.5 ϫ 10 6 /kg (a minimum of 1.5 ϫ 10 6 /kg CD34 + cells for each of the three cycles of highdose therapy) with an optimum target of Ͼ9 ϫ 10 6 /kg. 10 To ensure uniformity, each collection was divided into three separate bags, so that each re-infusion contained PBPCs collected from each day of apheresis. Cells were cryopreserved in 10% DMSO and stored in vapor-phase liquid nitrogen.
High-dose therapy
High-dose therapy was administered according to the following schedule; on day −4 patients received mesna (0.8 g/m 2 ) over 30 min followed immediately by cyclophosphamide (4 g/m 2 ) in four equally divided doses over 30 min, 2 h apart. Mesna (4 g/m 2 ) was administered as a continuous infusion over the first 24 h followed by 2.4 g/m 2 over the subsequent 24 h. Thiotepa was administered over 1 h in equally divided doses on days −4, −3, −2. Two hours after the administration of the thiotepa on day −2, docetaxel was administered as a 1 h infusion. Cryopreserved PBPC were thawed and infused on day 0. All patients received filgrastim 5 g/kg/day subcutaneously from day 1 until the ANC was Ͼ1.5 ϫ 10 9 /l for 3 consecutive days. Prophylactic ciprofloxacin, aciclovir and ranitidine were administered to all patients.
The planned interval between cycles was 35 days. Patients proceeded to the next cycle of HDT if they had not experienced unacceptable non-hemopoietic toxicity and the platelet count exceeded 70 ϫ 10 9 /L (optimum Ͼ100 ϫ 10 9 /l).
Maximum tolerated dose
Cohorts of four patients were enrolled at sequential dose levels ( Table 1) . Additional patients were accrued at a given dose level if a patient developed toxicity and did not complete all three cycles (see toxicity below). The maximum tolerated dose (MTD) was defined as that at which two or more patients developed dose-limiting toxicity (DLT) defined as NCI grade 4 non-hematological toxicity (excluding alopecia) or grade 3 neurological, cardiac or renal toxicity, or when two or more patients were unable to complete three cycles of HDT therapy because of hematological toxicity.
Statistical analysis
To compare ANC and platelet recovery between the three cycles of high-dose therapy (individual patient data sets) repeated measures ANOVA was used. Kaplan-Meier estimates of time to platelet and ANC recovery were performed and recovery with consecutive cycles were compared using the log-rank test. Survival and progression-free survival were calculated from the day of the first PBPC infusion. All results are expressed as two-sided P values. Statistical analysis was performed using GraphPad Prism Ver 2.01 and GraphPad StatMate Ver 1.00 for Windows 3.1. (GraphPad Software, San Diego, CA, USA).
Results
Patient characteristics
Eighteen patients with a median age of 45 years (range 26-57) were enrolled over a 12 month period ( Table 2 ). The majority of patients had metastatic disease (n = 15) with a median of three sites involved (range 1-4) with 11 patients having visceral metastatic disease. Three patients had locally advanced disease, two of whom were refractory to conventional-dose neoadjuvant therapy. Seventy-two percent of patients had received a prior anthracycline. A total of six patients (33%) were resistant (stable or progressive disease) to the conventional-dose therapy delivered immediately prior to PBPC mobilization with docetaxel. Eight patients (44%) had received paclitaxel prior to study entry.
Apheresis collections
All patients enrolled in the study obtained sufficient PBPCs to proceed to HDT. One patient required a second mobilization and collection to achieve the target autograft yield. The median autograft CD34+ content (to support each cycle of HDT) was 3.24 ϫ 10 6 /kg (1.82-7.46).
Dose intensity and non-hematopoietic toxicity
For the 18 patients, 44 of the planned 54 treatment cycles were delivered. Eleven patients completed all three cycles, four completed only two cycles and three completed only one cycle. As rapid hematopoietic recovery was observed after most cycles (see below), the subsequent cycle of HDT was delivered a median of 31 days after infusion of the PBPCs (range 24-66 days) ie 35 days between cycles of chemotherapy. Dose-limiting toxicities are detailed in Tables 3 and 4 . One patient on level 1 had delayed platelet recovery and thus did not proceed to further HDT. An additional patient was accrued to this dose level (n = 5). Two of the five patients developed grade 4 diarrhea (one associated with Clostridium difficile infection). One of these patients also had associated grade 4 mucositis. The incidence and severity of mucositis and diarrhea at this dose level were considered acceptable to proceed to the next dose level.
At dose level 2, no patient completed all three cycles. One patient withdrew consent and one had delayed platelet recovery after the second cycle. The remaining two patients Bone Marrow Transplantation developed severe grade 4 life-threatening interstitial pneumonitis (IP) manifested by high fevers, diffuse pulmonary interstitial infiltrate on CXR and CT scan with negative microbiological cultures on bronchoscopy. Both patients responded rapidly to steroid therapy with complete resolution of the interstitial pneumonitis (clinically and on repeat pulmonary function testing). One of these patients also had co-existent grade 4 mucositis. In view of the interstitial pneumonitis in two of four patients this level was considered to be dose-limiting.
As significant toxicity had also been observed at dose level 1, and there had been one episode of grade 2 interstitial pneumonitis, it was decided to investigate dose level 1a with a dose decrease of thiotepa and docetaxel (cyclophosphamide 4 g/m 2 , thiotepa 300 mg/m 2 and docetaxel 100 mg/m 2 ). At this level, there was no interstitial pneumonitis observed in the first four consecutive patients with one patient developing a DLT of grade 4 mucositis in association with grade 4 skin rash. The cohort was subsequently expanded to accrue an additional five patients. In these subsequent five patients on level 1a, there was one further DLT of grade 4 diarrhea, as well as one grade 3 interstitial pneumonitis (steroid responsive with no longterm sequelae and normalization of their lung function) and one grade 3 rash. This gave a total of 2/9 of patients at this dose level experiencing a DLT. Other milder toxicities are detailed in Table 4 . Of note, one patient had grade 2 peripheral neuropathy and one patient had grade 2 myalgia and no patients experienced any cortical neurological side-effects. There were no treatment-related deaths. Therefore, the recommended dose for subsequent studies is cyclophosphamide (4 g/m 2 ), thiotepa (300 mg/m 2 ) and docetaxel (100 mg/m 2 ).
Hematological toxicity and hemopoietic recovery
For all 44 cycles, the median time to ANC Ͼ1.0 ϫ 10 9 /l was 11 days (range 8-23) with no slowing of neutrophil recovery over consecutive cycles (P = 0.5615; log rank test). G-CSF was required for a median of 11 days (range 9-23 days) for each cycle. Febrile neutropenia occurred following 76% of all cycles and, when it occurred, lasted a median of 4 days. Admission to hospital was required following 76% of cycles with a median inpatient stay of 7 days (range 3-33 days). The reason for admission into hospital was febrile neutropenia in 92% of cases.
The median times to platelet recovery to greater than 20 ϫ 10 9 /l, 50 ϫ 10 9 /l and 100 ϫ 10 9 /l were 13 days (range 11-40), 18 days (range 12-70) and 26 days (range 18-220+), respectively. Platelet recovery was analyzed across the treatment cycles. When all 18 patients were analyzed together (n = 44 cycles of HDT) there was no difference in platelet recovery to 20 ϫ 10 9 /l (P = 0.9929; log-rank test), 50 ϫ 10 9 /l (P = 0.1400) or 100 ϫ 10 9 /l (P = 0.3032). However, we then analyzed only the patients who received all three cycles of planned HDT (n = 11). We observed that although there was no difference in platelet recovery (to 50 ϫ 10 9 /l) between cycles 1 and 2 (P = 0.1804) there was a delay across the three cycles (P = 0.0066; repeated measures ANOVA) (Figure 1) . Furthermore, for platelet recovery to Ͼ100 ϫ 10 9 /l, there was a slowing from cycle 1 to a Includes one patient with C. difficile infection. b Fluid retention severity grading was defined for peripheral edmea (E) and body cavity effusion. Grade 1 E was asymptomatic or dependent in evening only, grade 2 E was moderate functional impairment or dependent throughout the day and grade 3 was significant impairment or generalized anasarca. The patient with grade 3 edema had no peripheral edema but a symptomatic pleural effusion (negative cytology). /l in patients who received all three cycles of HDT (n = 11); P = 0.0066 by repeated measures ANOVA and P = 0.14 by log-rank test.
cycle 2 (P = 0.0303) and across all three cycles (P = 0.0315; repeated measures ANOVA). A median of three platelet transfusions and two packed red blood cell transfusions were required following each cycle of treatment.
Responses and survival
Of the 18 patients on this study, 15 were evaluable for response to the CDT prior to HDT (Table 5 ). Three patients underwent mobilization chemotherapy and subsequent HDT immediately following the diagnosis of MBC and were not evaluable (NE) for response to CDT but were evaluable for response to HDT. By defining patients with bone-only disease (n = 3) who had a positive bone scan but negative PET scan following HDT as 'PR (+ bone scan)', 17 patients were evaluable for response to HDT. Of these 17 patients, 16 achieved a response, with one patient having progressive disease (PD) during HDT. All eight patients with chemotherapy-responsive disease prior to HDT had a further response (five CRs, three PRs). Of the six patients who had resistant disease (stable or progressive) to CDT, five had a response. With a median follow-up of 12 months for all surviving patients (range 5- Table 5 Response to high-dose therapy CDT = conventional-dose therapy; HDT = high-dose therapy; PD = progressive disease, NE = not evaluable (for details see text).
a One patient had nodal disease at relapse and achieved a CR prior to HDT, all other patients in this group achieved a PR prior to HDT and had evaluable disease.
Bone Marrow Transplantation 16 months), the median PFS is 11 months. The median survival has not been reached ( Figure 2 ).
Discussion
We and other investigators have explored the use of repetitive HDT in MBC. Most investigators have attempted to repeat or combine established 'single-transplant' regimens or modify existing regimens by selective reductions in drug doses. Not unexpectedly, this has resulted in wide variation in the reported toxicities in these studies. [16] [17] [18] These results emphasize the need for careful dose-escalation studies of repetitive high-dose therapy. The most commonly used drugs in published repetitive high-dose therapy regimens have been the alkylating agents, carboplatin and the anthracyclines. Although the results of studies utilizing doseescalated anthracyclines are promising, [19] [20] [21] [22] our protocol did not incorporate these agents as we predicted that the population of patients considered for such therapies were likely to have previously failed an anthracycline-based regimen. This was the case with 72% having received a prior anthracycline. Indeed, the increasing use of anthracyclines in adjuvant treatments largely precludes the incorporation of anthracyclines into any HDT regimen for metastatic disease.
In a previous study of repetitive HDT for MBC, we demonstrated that three cycles of high-dose ifosfamide, thiotepa and conventional-dose paclitaxel (ITP) could be delivered with PBPC support. 9 However, because of three cases of ifosfamide-induced RTA we modified this regimen by substituting ifosfamide (10 g/m 2 ) with cyclophosphamide (4 g/m 2 ). A further modification was to substitute paclitaxel with docetaxel and to examine the feasibility of escalating the docetaxel dose. As in our previous study, nonhematological toxicity determined the MTD of our regimen. Indeed, dose-limiting toxicities of the cyclophosphamide/thiotepa/docetaxel regimen were interstitial pneumonitis and mucositis. The development of severe life-threatening interstitial pneumonitis in two patients at dose level 2 was surprising as only one patient at level 1 had developed interstitial pneumonitis (grade 2) and the only difference between levels one and two was the increase in docetaxel from 100 mg/m 2 to 125 mg/m 2 . Interstitial pneumonitis is a recognized toxicity, albeit rare, of thiotepa 23 and in our prior ITP study we did see reversible grade 2 interstitial pneumonitis in two of 23 patients. 9 Furthermore, severe interstitial pneumonitis has been reported following conventional-dose docetaxel. 24 Taken together, we felt that the cause of the interstitial pneumonitis was most likely related to the thiotepa/docetaxel combination, although it is not possible to exclude an interaction with cyclophosphamide. 25 We subsequently modified the protocol and reduced the dose of docetaxel (back to 100 mg/m 2 ) for the next cohort. Given the potential interaction of thiotepa with docetaxel in the development of interstitial pneumonitis, and the development of grade 4 mucositis in three of the nine patients in the first two dose levels, we simultaneously reduced the thiotepa dose (back to 300 mg/m 2 ). In the subsequent cohort (level 1a), there was reversible grade 3 interstitial pneumonitis observed in only one of nine patients, as well as reduction in the severity and incidence of mucositis. The other severe non-hemopoietic toxicities reported in occasional patients were diarrhoea and skin rash. Although the cumulative dose of thiotepa in this study was 900-1050 mg/m 2 , the typical neurological toxicity of a 'dementia-like syndrome' was not observed. 26 However, formal neuropsychiatric testing was not performed and subtle defects may not have been detected.
Other investigators have added docetaxel into repetitive HDT regimens for high-risk breast cancer. Indeed, it was successfully combined with a combination of epirubicin (200 mg/m 2 ) and cyclophosphamide (4 g/m 2 ) aiming to maintain the dose intensity of the latter two drugs. In this study docetaxel could be administered at a dose of 85 mg/m 2 per cycle. 27 Zimmerman et al, 28 like us, sought to combine a taxane with two alkylating agents (cyclophosphamide: 7.5 g/m 2 , thiotepa: 675 mg/m 2 ) but in a single transplant approach. In their phase I study, they were unable to dose-escalate continuous infusion paclitaxel beyond the conventional-dose range (MTD = 180 mg/m 2 ). 28 Other investigators have taken an alternative approach with a focus on dose-escalating the taxane. Gluck 29 Indeed, it could be argued that the combination of two alkylating agents adds only toxicity without additional efficacy and the focus should be on dose-escalating the taxane. However, the answer to this question can only be answered by a prospective comparative trial. Furthermore, recent evidence would indicate that docetaxel can only be escalated modestly even when administered alone with growth factor support; Mitchell et al 30 reported that at a dose of 170 mg/m 2 DLTs of neuropathy and skin toxicity were observed associated with substantial aesthenia (personal communication). Taken together, we believe that adding taxanes to HDT regimens without compromising the alkylating agents is a promising approach requiring further investigation of efficacy, particularly in patients who have had substantial exposure to anthracyclines where they cannot be incorporated into the HDT regimen.
The degree of hemopoietic toxicity observed with this regimen was anticipated. Although the re-admission rate for febrile neutropenia was high, the median length of inpatient stay was relatively short at 7 days and no patients treated at level 1a required opiate analgesia or parenteral nutrition for mucositis. This is of some importance as the regimen achieves substantial dose intensity while maintaining patients in the outpatient setting for the majority of their treatment. Indeed, with a general tendency to manage febrile neutropenia in the ambulatory setting the readmission rate could be reduced further. Although it remains to be seen whether repetitive HDT for breast cancer is superior to conventional-dose therapy, 31, 32 one potential advantage of this repeated 'mini-transplant' approach is the ability to treat patients in the out-patient setting, which has the potential to improve their quality-of-life (QL). Indeed, QL issues need to be incorporated into any subsequent phase II and III studies of HDT in breast cancer.
Although neutrophil recovery was not slowed over the three cycles of therapy, there was a significant delay in platelet recovery. Although no patients failed to recover their platelet count to Ͼ50 ϫ 10 9 /l, platelet recovery to Ͼ100 was very prolonged in some.
The high response rate in this group of patients is promising although longer follow-up is required. Based on these results, we have designed a multicenter phase III study which compares this HDT regimen of cyclophosphamide (4 g/m 2 ), thiotepa (300 mg/m 2 ) and docetaxel (100 mg/m 2 ) to conventional-dose docetaxel-based therapy as first-line treatment in patients with previously untreated MBC. Indeed, only until repetitive HDT is compared to conventional-dose therapy in the randomized setting (assessing the major endpoints of survival and QL) will the value of such an approach be truly defined.
